

K 4209WO - Sequence listing_ST25.txt
SEQUENCE LISTING

<110> KTB Tumorforschungsgesellschaft mbH
Tumorforschung GmbH, KTB

<120> Bisphosphonate-Prodrugs

<130> K 4209WO

<150> EP 11 001 551.9

<151> 2011-02-24

<160> 10

<170> PatentIn version 3.5

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Preferred peptide equence incorporated in the prodrug

<400> 1

Ala Leu Ala Leu

1

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Preferred peptide equence incorporated in the prodrug

<400> 2

Ser Ser Tyr Tyr Ser Arg

1

5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> cleavable linker

<400> 3

Ser Ser Tyr Tyr Ser Leu

1

5

<210> 4

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Preferred peptide sequence incorporated in the prodrug

<400> 4

K 4209WO - Sequence Listing_ST25.txt
Arg Ser Ser Tyr Tyr Ser Leu
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred peptide sequence incorporated in the prodrug
<400> 5

Phe Pro Lys Phe Phe Ser Arg Gln
1 5

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred peptide sequence incorporated in the prodrug

<220>
<221> nph
<222> (6)..(6)
<223> x = nitrophenylalanine
<400> 6

Lys Pro Ile Glu Phe Xaa Arg Leu
1 5

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred peptide sequence incorporated in the prodrug
<400> 7

Gly Pro Leu Gly Ile Ala Gly Gln
1 5

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Preferred peptide sequence incorporated in the prodrug
<400> 8

Gly Gly Gly Arg Arg
1 5

<210> 9
<211> 8

K 4209WO - Sequence listing_ST25.txt

<212> PRT

<213> Artificial Sequence

<220>

<223> Preferred peptide sequence incorporated in the prodrug

<400> 9

Gly Pro Gln Gly Ile Trp Gly Gln
1 5

<210> 10

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Preferred peptide sequence incorporated in the prodrug

<400> 10

Gly Phe Leu Gly
1